PRL3-zumab, a first-in-class humanized antibody for cancer therapy

Area of Science:

• Oncology
• Immunotherapy
• Drug Discovery

Background:

• Novel cancer therapies are needed, particularly for intracellular targets.
• PRL-3 is an intracellular phosphatase overexpressed in multiple cancers, including gastric cancer (GC).
• Elevated PRL-3 expression in GC correlates with poor patient survival.

Purpose of the Study:

• To develop and evaluate a humanized antibody (PRL3-zumab) targeting the intracellular oncoprotein PRL-3.
• To assess the therapeutic efficacy of PRL3-zumab in gastric cancer models.
• To elucidate the mechanism of action for PRL3-zumab.

Main Methods:

• Generation of a humanized antibody, PRL3-zumab, against PRL-3.
• In vitro and in vivo studies using human GC cell lines and orthotopic tumor models.
• Assessment of tumor growth inhibition, recurrence prevention, and mechanism of action.

Main Results:

• PRL3-zumab specifically targeted and blocked PRL-3 positive gastric tumors.
• PRL3-zumab demonstrated superior efficacy as a monotherapy compared to combination with 5-fluorouracil.
• The antibody prevented tumor recurrence and demonstrated a novel mechanism involving externalization of intracellular PRL-3.
• PRL-3 protein was overexpressed in 85% of GC samples but not in normal tissues.

Conclusions:

• PRL3-zumab represents a first-in-class antibody therapy for targeting intracellular PRL-3 in cancer.
• This approach offers a potential breakthrough for treating gastric cancer and other PRL-3-driven malignancies.
• The study establishes a framework for developing antibodies against other intracellular oncotargets.